Published in Antimicrob Agents Chemother on February 01, 1977
Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother (2008) 3.12
Simplified bioassay method for measurement of flucytosine or ketoconazole. J Clin Microbiol (1985) 1.52
Antifungal resistance and new strategies to control fungal infections. Int J Microbiol (2011) 1.44
Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrob Agents Chemother (1978) 1.38
In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother (2000) 1.32
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother (2013) 1.16
The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol (1999) 1.12
In vitro activities of miconazole, miconazole nitrate, and ketoconazole alone and combined with rifampin against Candida spp. and Torulopsis glabrata recovered from cancer patients. Antimicrob Agents Chemother (1980) 1.06
Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother (1986) 0.98
Pharmacokinetics of amphotericin B and flucytosine. Postgrad Med J (1979) 0.96
A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid. Antimicrob Agents Chemother (2013) 0.89
Rapid determination of 5-fluorocytosine levels in blood. J Clin Microbiol (1984) 0.88
Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med (2014) 0.85
Improved procedure for determination of flucytosine in human blood plasma by high-pressure liquid chromatography. Antimicrob Agents Chemother (1984) 0.83
Antifungal agents in neonatal systemic candidiasis. Antimicrob Agents Chemother (1995) 0.82
5-fluorocytosine susceptibility of pathogenic fungi in the presence of allopurinol: potential for improving the therapeutic index of 5-fluorocytosine. Antimicrob Agents Chemother (1983) 0.75
In vitro studies with 5-fluorocytosine. Appl Microbiol (1969) 8.01
Serologic tests in diagnosis and prognosis of cryptococcosis. JAMA (1966) 2.87
The metabolism of 5-fluorocytosine-2-14-C and of cytosine-14-C in the rat and the disposition of 5-fluorocytosine-2-14-C in man. Biochem Pharmacol (1966) 2.72
Candida endocarditis treated with 5-fluorocytosine. Br Med J (1971) 2.20
Rapid, simple bioassay for 5-fluorocytosine in the presence of amphotericin B. Antimicrob Agents Chemother (1975) 2.17
Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis (1975) 1.88
The kinetics of 5-fluorocytosine elimination in man. Aust N Z J Med (1972) 1.81
Chemistry and biology of the polyene macrolide antibiotics. Bacteriol Rev (1973) 1.76
Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. Ann Intern Med (1974) 1.63
Amphotericin B. Old drug, new therapy.?2110. JAMA (1975) 1.61
Torulopsis glabrata renal infection. Am J Med (1974) 1.48
5-fluorocytosine and urinary candidiasis. Br Med J (1971) 1.34
Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy (1973) 1.19
Simple assay for 5-fluorocytosine in the presence of amphotericin B. Antimicrob Agents Chemother (1976) 1.05
Severe candidiasis associated with thymic dysplasia, IgA deficiency, and plasma antilyMPHOCYTE EFFECTS. Pediatrics (1970) 0.91
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study. Ann Intern Med (1987) 5.74
Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med (1993) 4.72
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis (2001) 4.01
Group C streptococcal bacteremia: analysis of 88 cases. Rev Infect Dis (1991) 3.88
Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med (1994) 3.32
Methicillin-resistant Staphylococcus aureus: colonization and infection in a long-term care facility. Ann Intern Med (1991) 3.03
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med (1994) 2.60
Use of a colorimetric system for yeast susceptibility testing. J Clin Microbiol (1995) 2.54
Bronchoscopy with bronchoalveolar lavage in tuberculosis and fungal infections. Chest (1991) 2.42
The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis (2001) 2.25
Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis (2007) 2.09
Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis (1996) 2.09
Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin Infect Dis (2000) 2.08
Alopecia associated with fluconazole therapy. Ann Intern Med (1995) 2.05
Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med (1992) 2.01
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med (1993) 1.99
Staphylococcus aureus nasal colonization in a nursing home: eradication with mupirocin. Infect Control Hosp Epidemiol (1990) 1.90
Single-concentration broth microdilution test for detection of high-level aminoglycoside resistance in enterococci. J Clin Microbiol (1987) 1.85
Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphylococcal isolates. Antimicrob Agents Chemother (1996) 1.83
Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 1.80
Methicillin-resistant Staphylococcus aureus (MRSA): a briefing for acute care hospitals and nursing facilities. The AHA Technical Panel on Infections Within Hospitals. Infect Control Hosp Epidemiol (1994) 1.79
Bronchoalveolar lavage for diagnosing acute bacterial pneumonia. J Infect Dis (1987) 1.75
Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol (1988) 1.69
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther (1997) 1.64
Gentamicin resistance plasmids of enterococci from diverse geographic areas are heterogeneous. J Infect Dis (1988) 1.60
Azidothymidine neurotoxicity. Lancet (1986) 1.58
Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function. J Lab Clin Med (1978) 1.57
Histoplasmosis in immunosuppressed patients. Am J Med (1978) 1.54
Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections. Antimicrob Agents Chemother (1987) 1.53
The epidemiology of pseudallescheriasis complicating transplantation: nosocomial and community-acquired infection. Mycoses (1990) 1.53
Histoplasma capsulatum polysaccharide antigen detection in diagnosis and management of disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am J Med (1989) 1.52
Purulent pneumococcal pericarditis. A continuing problem in the antibiotic era. Am J Med (1973) 1.51
Cell-mediated immunity in humans during viral infection. I. Effect of rubella on dermal hypersensitivity, phytohemagglutinin response, and T lymphocyte numbers. Infect Immun (1974) 1.50
High-level aminoglycoside-resistant enterococci. Colonization of nursing home and acute care hospital patients. Arch Intern Med (1987) 1.49
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Torulopsis glabrata renal infection. Am J Med (1974) 1.48
Increasing resistance of Staphylococcus aureus to ciprofloxacin. Antimicrob Agents Chemother (1990) 1.45
Risk factors for colonization with yeast species in a Veterans Affairs long-term care facility. J Am Geriatr Soc (1998) 1.45
Intermittent urethral catheterization in the elderly. J Am Geriatr Soc (1989) 1.43
Detection and characterization of mupirocin resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1993) 1.43
Group B streptococcal prosthetic joint infection following sigmoidoscopy. Clin Infect Dis (1992) 1.42
Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother (1992) 1.40
Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1995) 1.37
Emergence of nosocomial methicillin-resistant Staphylococcus aureus and therapy of colonized personnel during a hospital-wide outbreak. Infect Control (1987) 1.36
Cryptococcus laurentii lung abscess. Am Rev Respir Dis (1981) 1.35
Nasal carriage of and infection with Staphylococcus aureus in HIV-infected patients. Ann Intern Med (1999) 1.32
Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 1.32
Rapid identification of Staphylococcus aureus by using lysostaphin sensitivity. J Clin Microbiol (1980) 1.30
Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc (1994) 1.29
Enterococcal superinfection in patients treated with ciprofloxacin. J Antimicrob Chemother (1988) 1.29
Effect of viral and bacterial pneumonias on cell-mediated immunity in humans. Infect Immun (1976) 1.29
Cardiobacterium hominis endocarditis: Two cases and a review of the literature. Eur J Clin Microbiol Infect Dis (2006) 1.28
Evaluation of the BACTEC antimicrobial removal system for detection of bacteremia. J Clin Microbiol (1983) 1.27
Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis (1995) 1.21
Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis (2008) 1.20
Fungaemia due to Cryptococcus laurentii and a review of non-neoformans cryptococcaemia. Mycoses (1999) 1.20
Association of Reye's syndrome with viral infection. Lancet (1974) 1.17
The continuing utility of bronchoalveolar lavage to diagnose opportunistic infection in AIDS patients. Am J Med (1994) 1.14
Salmonella meningitis. Occurrence in an adult. Arch Neurol (1979) 1.13
Cellular immune response to cytomegalovirus infection after renal transplantation. Infect Immun (1978) 1.13
Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS (1994) 1.12
Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin. Am J Med (1990) 1.12
Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations. Ther Drug Monit (1991) 1.11
Detection of cryptococcal antigen. Comparison of two latex agglutination tests. Am J Clin Pathol (1981) 1.11
Rhodotorula fungaemia: a life-threatening complication of indwelling central venous catheters. Mycoses (1993) 1.10
Outbreak of sternal surgical site infections due to Pseudomonas aeruginosa traced to a scrub nurse with onychomycosis. Clin Infect Dis (2001) 1.10
Mupirocin resistance: clinical and molecular epidemiology. Infect Control Hosp Epidemiol (1995) 1.10
Hospital-acquired infective endocarditis. Arch Intern Med (1988) 1.09
Use of the protected specimen brush in patients with endotracheal or tracheostomy tubes. Chest (1987) 1.09
Trends in species causing fungaemia in a tertiary care medical centre over 12 years. Mycoses (2001) 1.09
Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis (1977) 1.08
Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1994) 1.07
Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1994) 1.07
Torulopsis glabrata: azole susceptibilities by microdilution colorimetric and macrodilution broth assays. J Clin Microbiol (1995) 1.06
Cell-mediated immunity in patients on long-term haemodialysis. Clin Exp Immunol (1975) 1.06
Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis (2001) 1.05
Simple assay for 5-fluorocytosine in the presence of amphotericin B. Antimicrob Agents Chemother (1976) 1.05
Recurrent pseudobacteremias traced to a radiometric blood culture device. Infect Control (1987) 1.05
Nosocomial infection with gentamicin-carbenicillin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (1976) 1.04
Cryptococcal endophthalmitis: case report and review. Clin Infect Dis (1992) 1.04
Antimicrobial resistance of Haemophilus species in patients with chronic bronchitis. Am Rev Respir Dis (1979) 1.03
Effect of hand cleansing with antimicrobial soap or alcohol-based gel on microbial colonization of artificial fingernails worn by health care workers. Clin Infect Dis (2001) 1.03
Candidiasis. A diagnostic and therapeutic challenge. Postgrad Med (1986) 1.03
Mucormycosis: association with deferoxamine therapy. Am J Med (1989) 1.02
Long-term survival of vancomycin-resistant Enterococcus faecium on a contaminated surface. Infect Control Hosp Epidemiol (1996) 1.01
Colonization with vancomycin-resistant Enterococcus faecium: comparison of a long-term-care unit with an acute-care hospital. Infect Control Hosp Epidemiol (1997) 1.01
Septic arthritis in the elderly. J Am Geriatr Soc (1985) 1.00
Prosthetic joint infections in the elderly. Am J Med (1990) 1.00
Role of CD40 ligand signaling in defective type 1 cytokine response in human immunodeficiency virus infection. J Infect Dis (2001) 0.99
Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium. Diagn Microbiol Infect Dis (1996) 0.99
Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin. Diagn Microbiol Infect Dis (1995) 0.98
Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons. Clin Infect Dis (2001) 0.98
Chronic candidal meningitis: an uncommon manifestation of candidiasis. Clin Infect Dis (1994) 0.98
Invasive fungal infections in patients with chronic mucocutaneous candidiasis. Arch Intern Med (1981) 0.98
Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group. Am J Med (1993) 0.97